Eli Lilly Reports P-III (BRUIN CLL-322) Trial Data on Jaypirca Combination for CLL/SLL

Why It Matters

The results could broaden Jaypirca’s indication, offering a more durable, chemo‑free option for heavily pre‑treated CLL patients and strengthening Lilly’s position in the competitive hematology market.

Key Takeaways

• Jaypirca combo extended median PFS vs control arm
• Benefit consistent across BTK‑inhibitor‑pretreated patients
• Trial followed patients for ~2 years before therapy‑free interval
• Data to support label expansion later this year

Pulse Analysis

Eli Lilly’s third‑stage BRUIN CLL‑322 study evaluated pirtobrutinib, marketed as Jaypirca, in combination with venetoclax and rituximab for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These diseases affect over 200,000 adults in the United States, and many have already progressed after covalent BTK inhibitors such as ibrutinib. By pairing a non‑covalent BTK inhibitor with a BCL‑2 antagonist and an anti‑CD20 antibody, the trial aimed to deepen responses and potentially allow a treatment‑free interval after two years of continuous therapy.

The trial met its primary endpoint, showing a statistically significant extension of progression‑free survival (PFS) versus venetoclax‑rituximab alone, with the benefit persisting across clinically relevant subgroups, including patients previously exposed to covalent BTK inhibitors. Although overall survival data remain immature, an early trend favors the three‑drug regimen. These findings position Jaypirca as a potential new backbone for later‑line CLL therapy and set the stage for a regulatory filing later this year, which could broaden the drug’s label beyond its current indication for BTK‑inhibitor‑naïve patients.

Beyond the immediate clinical impact, the data underscore a shift toward combining targeted agents to achieve deeper remissions and, eventually, treatment‑free periods—a goal that aligns with patient‑centric care models. Competitors such as AbbVie’s venetoclax‑based combos and Roche’s BTK inhibitors will need to demonstrate comparable durability to stay competitive. For Lilly, the success of Jaypirca adds momentum to its broader oncology pipeline, which includes several late‑stage candidates. Analysts anticipate that a label expansion could lift Lilly’s CLL market share and reinforce its reputation as an innovator in precision hematology.